Overview
- 3 inspections across 3 sites are on record.
- 9 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2023-05-24.
At a glance
Inspections
3
Sites
3
Observations
9
Career since
May 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 24 May 2023 | Human Drugs | On file |
| BIOCON SDN.BHD. | 21 Feb 2020 | Human Drugs | View 483 → |
| Ocular Therapeutix, Inc. | 4 May 2017 | Human Drugs | View 483 → |
Sites inspected
Takeda Pharmaceutical Company LimitedHikari, Japan1 insp.
BIOCON SDN.BHD.Iskandar Puteri, Malaysia1 insp.
Ocular Therapeutix, Inc.Bedford, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Bingchen Du1 shared
Holly Brevig1 shared
Thuy T Nguyen1 shared
Laurimer Kuilan-Torres1 shared
Shawn E Larson1 shared
Nealie C Newberger1 shared
Full investigator report
Get the verbatim findings behind Vidya B Pai's 9 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site